Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of TCB008 in COVID-19
NCT04834128Phase 2Withdrawn
- Sponsor
- TC BioPharm
- Start
- Dec 2021
- Primary completion
- Apr 2022
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of TCB008 in coronavirus disease 2019 (COVID-19), sponsored by TC BioPharm. Planned start Dec 2021; status: withdrawn.
02
Drugs
TCB008
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04834128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04834128.